Zacks Investment Research downgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a buy rating to a hold rating in a research report report published on Tuesday, September 18th.

According to Zacks, “Endo is in the process of redefining its business, given the persistent decline in the generic business and withdrawal of opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017.  The focus now is on sterile injectables and Xiaflex.  Sales of Xiaflex are being driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Revenues from the sterile injectables business are being driven by the continued growth of Adrenalin. The business is poised to become Endo's core business. While the turnaround might take time, the company seems to be on the right track. Shares have outperformed the industry in the year so far. However, the generic business is expected to face further challenges. Competition is expected to intensify further in 2018.”

A number of other analysts also recently commented on ENDP. Deutsche Bank set a $10.00 target price on shares of Endo International and gave the stock a buy rating in a report on Friday, June 1st. BidaskClub upgraded shares of Endo International from a sell rating to a hold rating in a report on Friday, June 8th. Citigroup upgraded shares of Endo International from a neutral rating to a buy rating and set a $11.00 target price on the stock in a report on Wednesday, June 27th. B. Riley boosted their target price on shares of Endo International from $10.00 to $13.00 and gave the stock a buy rating in a report on Thursday, June 28th. Finally, Cantor Fitzgerald set a $12.00 price target on shares of Endo International and gave the company a hold rating in a report on Monday, July 23rd. Fifteen analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $14.55.

Endo International stock traded up $0.71 during midday trading on Tuesday, reaching $17.51. 6,318,976 shares of the stock traded hands, compared to its average volume of 5,560,697. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $18.16. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of 4.56, a PEG ratio of 3.23 and a beta of 0.71. The company has a quick ratio of 0.91, a current ratio of 1.07 and a debt-to-equity ratio of -132.64.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Wednesday, August 8th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.22. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The company had revenue of $714.70 million for the quarter, compared to the consensus estimate of $679.72 million. During the same period in the previous year, the firm earned $0.93 EPS. Endo International’s revenue was down 18.4% on a year-over-year basis. Research analysts expect that Endo International will post 2.6 earnings per share for the current year.

In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. United Services Automobile Association grew its position in Endo International by 16.7% in the second quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock worth $391,000 after acquiring an additional 5,933 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Endo International by 13.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after buying an additional 284,599 shares during the period. Schroder Investment Management Group boosted its holdings in shares of Endo International by 78.1% during the 2nd quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after buying an additional 327,775 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Endo International by 7.2% during the 2nd quarter. Van ECK Associates Corp now owns 368,590 shares of the company’s stock worth $3,476,000 after buying an additional 24,693 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Endo International by 27.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 104,155 shares of the company’s stock worth $994,000 after buying an additional 22,644 shares during the period. 98.43% of the stock is owned by institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.